

[Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism \(https://mentis-study-confirms-oral-microdose-psilocybin-treatment-of-autism/\)](https://mentis-study-confirms-oral-microdose-psilocybin-treatment-of-autism/)

February 16, 2022 6:00 am Published by [Nova Mentis Life Science Corp.](https://novamentis.ca/news/author/adfsdhrfvvh/) (<https://novamentis.ca/news/author/adfsdhrfvvh/>).



Vancouver, British Columbia – February 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that Nova Mentis successfully completed an oral microdose study at the University of Rome, Italy. The results exceeded all expectations with the findings that a very low dose of the Company’s proprietary psilocybin significantly modulated a genetic model of fragile X syndrome (FXS).

“The science team led by Dr. Hausman, together with Dr. Viviana Trezza from Roma Tre University, continues to deliver promising preclinical results. The recent formulation results,” says Will Rascan, CEO of NOVA. “The clear positive data is critical as we prepare to submit our clinical trial application to Health Canada for fragile X syndrome.”

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder for which no treatments exist. Fragile X syndrome (FXS) is the most common form of ASD (1). The aim of the present study was to evaluate various oral doses of the company’s proprietary psilocybin in a rat model of FXS. A major question to be addressed was the potential treatment of choice in ASD, as compared to single dose macrodose therapy with associated hallucinogenic and other side effects.

Psilocybin efficacy was tested in FXS, in the Fmr1 knock-out (Fmr1 KO) rat (Fmr1-Δexon 8) – an established genetic model of FXS (1). Wild type control and Fmr1 KO rats were treated with 0.1 mg/kg or 0.3 mg/kg psilocybin on other day for 6 treatments, over a 2-week period, and on day 18 underwent object recognition testing. We had great results! Both 0.1 and 0.3 mg/kg were effective. Moreover, the 0.1 mg/kg worked best, and did not have any apparent side effects. The 0.1 mg/kg dose in the rat translates into approximately 1.5 mg oral dose in humans.

“I am elated to be able to report to the medical community that at long last we may have opened the door to treatment of ASD, an unmet medical need, that has plagued our society for decades,” says Dr. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “The rat model that we used mimics key autistic-like features in humans and the study results strongly suggest that psilocybin may be a viable treatment for FXS.”

FXS. Moreover, this positive response in the rat of every other day oral 0.1 mg/kg psilocybin, equivalent approximately to a 1.5 mg dose in a 70 kg person, may be a promising treatment for FXS, and perhaps have a longer term constructive neuroplastic response in the brain without the need for large doses of psychedelic drugs with associated risks.

Financing

In addition, the Company announces a non-brokered private placement of up to \$1,000,000 (the “Placement”).

The Company will issue up to 20,000,000 units at a purchase price of \$0.05 per unit. Each unit will consist of common share of the Company and one transferable warrant to purchase one additional common share at an exercise price of \$0.075 for a period of 18 months from the closing date.

The Company will use the proceeds from the Placement towards the launch of its ASD observational study, Health Canada Phase 2A CTA and general working capital. The Placement is subject to the policies of the Canadian Securities Exchange. All securities issued under the Placement will be subject to a statutory hold period of four months and one day.

References:

- Schiavi S, Carbone E, Melancia F, Buzzelli V, Manduca A, Campolongo P, Pallottini V, Trezza V. [Perinatal supplementation with omega-3 fatty acids corrects autistic-like behaviors based on FMR1 deletion in rats.](https://pubmed.ncbi.nlm.nih.gov/32912100/) (<https://pubmed.ncbi.nlm.nih.gov/32912100/>). Nutr Neurosci. 2020 Sep 11:1-14. doi: 10.1080/1028415X.2020.1819107.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has received orphan drug designation in both the United States and European Union.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome.

For further information on the Company, please visit www.novamentis.ca (<http://www.novamentis.ca>) or email info@novamentis.ca (<mailto:info@novamentis.ca>).

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentisisc

Instagram: @novamentisisc

Facebook: @novamentisisc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the accuracy or completeness of this information.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties, results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed in this news release. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "will," "would," "may," "could" or "should" occur.

SOURCE: NOVA MENTIS LIFE SCIENCE CORP.

[_\(/#facebook\)](#), [_\(/#twitter\)](#), [_\(/#linkedin\)](#), [_\(/#email\)](#),
[_\(/https://www.addtoany.com/share?url=https%3A%2F%2Fnovamentis.ca%2Fnews%2Fstudy-confirms-oral-microdose-psilocybin-treatment-of-autism%2F&title=Nova%20Mentis%20Study%20Confirms%20Oral%20Microdose%20\)](https://www.addtoany.com/share?url=https%3A%2F%2Fnovamentis.ca%2Fnews%2Fstudy-confirms-oral-microdose-psilocybin-treatment-of-autism%2F&title=Nova%20Mentis%20Study%20Confirms%20Oral%20Microdose%20)

[Back to News](#)

Corporate Head Office

Phone: 778-819-0244 (tel:7788190244)
Toll Free: 1-833-542-5323
Email: info@novamentisisc.com

Transfer Agent: Computershare
Tel: 604-661-9400 (tel:6046619400)


Auditor: Smythe LLP
Tel: 604-687-1231 (tel:6046871231)

Legal Counsel: Richards Buell Sutton LLP
Tel: 604-682-3664 (tel:604-682-3664)
<https://www.rbs.ca/> (<https://www.rbs.ca/>)

Contact Us

Address:
700-838 West Hasting Street Vancouver, B.C. Canada
V6C 0A6
Phone number:
778-819-0244
Toll Free:
1-833-542-5323
E-mail:
info@novamentis.ca

Follow Us


<https://www.youtube.com/channel/UCXD1Nhg8ihg2K6obL3->
<https://www.facebook.com/novamentisisc/>
<https://twitter.com/novamentisisc/>

Latest from Twitter

Tweets by @NovaMentisLSC

Nova Mentis Life Science Corp. Retweeted
 **Psilocybin Alpha**
@PsilocybinAlpha
Nova Mentis **\$NOVA** Study Confirms Oral Microdose Psilocybin Treatment of Autism

"a very low dose of the Company's proprietary psilocybin significantly modulated behavioural and cognitive defects, such as recognition memory, in a genetic model of FXS." psilocybinalpha.com/news/nova-ment...


Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of A...
VANCOUVER, BC, Feb. 16, 2022 /CNW/ – Nova Mentis Life Science Corp. (...
psilocybinalpha.com

Subscribe

Subscribe to our mailing list

**WEBSITE
POWERED BY
100%
RENEWABLE
ENERGY** (<https://whc.ca/green-powered/?aff=3153&gbid=3en>)

